Magical cancer drugs, but at what cost? Price tag may be a challenge for Juno, Novartis

Cutting-edge cancer treatments from Switzerland's Novartis AG and Seattle's own Juno Therapeutics show great promise in clinical trials, but might face roadblocks when it comes to the costs of getting those drugs to patients, the Wall Street Journal recently reported...